Dr. Michel Goldman (born 1 January 1955) is a Belgian medical doctor specialized in immunology and internal medicine. He is the Founder of the Institute for Interdisciplinary Innovation in healthcare (I3h) at the Université libre de Bruxelles.
He was the first Executive Director of the Innovative Medicines Initiative (IMI), from 2009 to 2014. With a €2 billion budget provided jointly by the European Federation of Pharmaceutical Industries and Associations and the European Commission, he launched public-private consortia in areas of major importance, including antimicrobial resistance, Alzheimer’s dementia and drug safety.
Dr. Goldman is the Editor-in-Chief of Frontiers in Medicine, a Board member of the French National Institute of Health and Medical Research (INSERM), the European Tuberculosis Vaccine Initiative and the Friends of the Global Fund Europe. He also serves as a member of the Cancer Mission Assembly of the European Commission and of the Leadership Group of Davos Alzheimer’s Collaborative. He is the President of the Belgian AstraZeneca Foundation and of the Belgian Kid’s Fund.
Dr. Goldman is a laureate of the Lucien Steinberg Prize (shared with Pr. Peter Piot, 1997), of the Quinquennial Prize of the Belgian National Fund of Scientific Research (2000), and of the Spinoza chair at the University of Amsterdam (2001). In 2007, Michel Goldman was awarded the degree of Doctor Honoris Causa of the Université of Lille.